73819-26-8
73819-26-8 structure
- Name: Furamidine
- Chemical Name: Furamidine
- CAS Number: 73819-26-8
- Molecular Formula: C18H16N4O
- Molecular Weight: 304.346
- Catalog: Signaling Pathways Epigenetics Histone Methyltransferase
- Create Date: 2019-12-19 18:26:48
- Modify Date: 2023-02-05 11:17:51
-
Furamidine (DB75) is abisbenzamidine derivative and an antiparasite agent. Furamidine is a potent, reversible and competitive tyrosyl-DNA phosphodiesterase 1 (TDP-1) inhibitor. Inhibition of TDP-1 by Furamidine is effective both with single- and double-stranded DNA substrates but is slightly stronger with the duplex DNA. Furamidine is also a selective and cell-permeable protein arginine methyltransferase 1 (PRMT1) inhibitor with an IC50 of 9.4 μM. Furamidine is selective for PRMT1 over PRMT5, PRMT6, and PRMT4 (CARM1) (IC50s of 166 µM, 283 µM, and >400 µM, respectively)[1][2][3].
| Name | Furamidine |
|---|---|
| Synonyms |
Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis-
4,4'-furan-2,5-diyldibenzenecarboximidamide 4,4'-(2,5-Furandiyl)dibenzenecarboximidamide MFCD01656960 |
| Description | Furamidine (DB75) is abisbenzamidine derivative and an antiparasite agent. Furamidine is a potent, reversible and competitive tyrosyl-DNA phosphodiesterase 1 (TDP-1) inhibitor. Inhibition of TDP-1 by Furamidine is effective both with single- and double-stranded DNA substrates but is slightly stronger with the duplex DNA. Furamidine is also a selective and cell-permeable protein arginine methyltransferase 1 (PRMT1) inhibitor with an IC50 of 9.4 μM. Furamidine is selective for PRMT1 over PRMT5, PRMT6, and PRMT4 (CARM1) (IC50s of 166 µM, 283 µM, and >400 µM, respectively)[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
Tyrosyl-DNA phosphodiesterase 1 (TDP-1)[1] Parasite[2] IC50: 9.4 μM (Protein arginine methyltransferase 1 (PRMT1)); 166 µM (PRMT5), 283 µM (PRMT6) and >400 µM (PRMT4)[2] |
| In Vitro | Furamidine (compound 1; 20 μM; 72 hours; leukemia cell lines) inhibits cell growth for most of the leukemia cell lines except HEL cells which have JAK2V617F mutations[2]. Furamidine (compound 1; 20 μM; 15 hours; 293T cells) treatment significantly reduces the expression level of the methylated GFP-ALY protein in 293T cells[2]. Furamidine binds duplex DNA in the DNA minor groove selectively at AT rich sites [(A/T)4]. Furamidine can also intercalate between GC base pairs of duplex DNA. Furamidine could therefore interfere with DNA processing enzymes such as TDP-1[1]. Cell Viability Assay[2] Cell Line: Meg-01, K562, HL-60, NB4, MOLM13, HEL, CMK, CMY, CMS and CHRF cells Concentration: 20 μM Incubation Time: 72 hours Result: Inhibited cell growth for most of the leukemia cell lines except HEL cells which have JAK2V617F mutations. Western Blot Analysis[2] Cell Line: 293T cells Concentration: 20 μM Incubation Time: 15 hours Result: The expression level of the methylated GFP-ALY protein is significantly reduced. |
| In Vivo | Furamidine (1 mg/kg; intraperitoneal injection; 3 times a week and repeated every 4 weeks; for 34 weeks; female NZB/NZW mice) and Irinotecan combined treatment suppresses proteinuria and prolongs survival of lupus-prone NZB/NZW mice. The combination treatment does not change the levels of anti-dsDNA antibodies[3]. Animal Model: Female NZB/NZW mice (6-week-old) with Irinotecan (1 mg/kg)[3] Dosage: 1 mg/kg Administration: Intraperitoneal injection; 3 times a week and repeated every 4 weeks; for 34 weeks Result: Suppressed proteinuria and prolongs survival of lupus-prone NZB/NZW mice combined with Irinotecan. |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 482.4±55.0 °C at 760 mmHg |
| Molecular Formula | C18H16N4O |
| Molecular Weight | 304.346 |
| Flash Point | 245.6±31.5 °C |
| Exact Mass | 304.132416 |
| LogP | 1.89 |
| Vapour Pressure | 0.0±1.2 mmHg at 25°C |
| Index of Refraction | 1.678 |
| Hazard Codes | Xi |
|---|